A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis

2013224 citationsJournal Article

Authors

The data suggest that eculizumab may have a role in treating severe, refractory MG.

Good health and well-being

Published in: Muscle & Nerve

Volume 48, Issue 1, pp. 76-84

Field-Weighted Citation Impact: 11.23